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Abstract
Members of the solute carrier family 6 (SLC6) of sodium- and (sometimes chloride-) dependent neurotransmitter
transporters [29, 22, 70] are primarily plasma membrane located and may be divided into four subfamilies that
transport monoamines, GABA, glycine and neutral amino acids, plus the related bacterial NSS transporters [99].
The members of this superfamily share a structural motif of 10 TM segments that has been observed in crystal
structures of the NSS bacterial homolog LeuTAa, a Na+-dependent amino acid transporter from Aquiflex aeolicus
[126] and in several other transporter families structurally related to LeuT [45].
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